Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.
Division of Clinical Studies, The Institute of Cancer Research, London, UK.
Future Oncol. 2017 Oct;13(24):2151-2157. doi: 10.2217/fon-2017-0210. Epub 2017 Jul 26.
The outcome for patients with unresectable/metastatic soft tissue sarcoma remains poor with few treatment options. In the first line setting, a number of randomized trials have shown no difference in overall survival between combination anthracycline schedules and single agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-α, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to approval of olaratumab in combination with doxorubicin in adult anthracycline-naive unresectable soft tissue sarcoma. In this review, we describe some of the preclinical and early clinical data of olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas.
无法切除/转移性软组织肉瘤患者的预后仍然较差，治疗选择有限。在一线治疗中，多项随机试验表明，联合蒽环类方案与单药多柔比星在总生存期方面没有差异。多柔比星联合或不联合 PDGFR-α 单克隆抗体奥拉单抗的 Ib/期随机 II 期试验显示，奥拉单抗组的中位总生存期有显著差异。该试验的结果导致批准奥拉单抗与多柔比星联合用于成人蒽环类药物初治不可切除的软组织肉瘤。在这篇综述中，我们描述了奥拉单抗在肉瘤中的一些临床前和早期临床数据、Ib/II 期试验以及正在进行的奥拉单抗在肉瘤中的试验。
